We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02879669
Recruitment Status : Unknown
Verified October 2020 by Targovax ASA ( Targovax Oy ).
Recruitment status was:  Active, not recruiting
First Posted : August 26, 2016
Last Update Posted : October 8, 2020
Sponsor:
Collaborator:
Theradex
Information provided by (Responsible Party):
Targovax ASA ( Targovax Oy )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The trial is an open-label, parallel group, multicentre trial that will recruit a total of 30 patients with malignant pleural mesothelioma. The trial will be conducted in 2 phases: a non-randomised safety phase and a randomised phase. The safety phase will consist of a lead-in cohort of 6 patients treated with ONCOS 102 and pemetrexed/cisplatin. The randomised phase will not commence until the DSMB has deemed the safety lead-in data appropriate for continuation. A total of 24 patients will be included in the randomised phase; 14 patients will be randomised to receive ONCOS 102 and pemetrexed/cisplatin, and 10 patients will receive pemetrexed/cisplatin alone. If cisplatin is seen to be too toxic after one or more cycles, the patient may change to carboplatin during the study. Furthermore, if treatment with cisplatin is deemed to be too toxic by the investigator due to age, presence of neurological toxicities or other relevant medical conditions, carboplatin can be administered from start of study. The trial's main objectives are determination of safety, immune activation, clinical response and the correlation between clinical outcome and the immunological data.

Condition or disease Intervention/treatment Phase
To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy Biological: ONCOS-102 Drug: Pemetrexed/cisplatin (carboplatin) Drug: Cyclophosphamide Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Study Start Date : June 2016
Actual Primary Completion Date : May 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mesothelioma Safety

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: ONCOS-102+cyclophosphamide+pemetrexed/cisplatin (carboplatin)
ONCOS-102 will be administered in a priming cycle (Cycle 1) comprising injections on Days 1, 4, 8 and 36, followed by two treatment cycles at intervals of 6 weeks (Cycle 2, Day 78 and Cycle 3, Day 120). Pre-treatment with an i.v. bolus of cyclophosphamide (CPO) will be given 1 to 3 days before the first administration of ONCOS-102 (Cycle 1, Day 1) and before administration of Cycle 2 of ONCOS-102 (Day 78). Patients will also receive pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 22 and continuing as applicable during the study period of 6 cycles of pemetrexed/cisplatin (carboplatin) in combination with ONCOS-102.
 Biological: ONCOS-102
Drug: Pemetrexed/cisplatin (carboplatin)
Drug: Cyclophosphamide
Active Comparator: Pemetrexed/cisplatin (carboplatin)
Patients will be treated with pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 1, and continuing as applicable during the study period of 6 cycles of chemotherapy. Patients will be monitored regularly for immunological assessment (PBMCs) including Month 9 and Month 12 (i.e., after the end of study visit), and will be followed up for survival every 3 months until end of life.
 Drug: Pemetrexed/cisplatin (carboplatin)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of patients with any (Serious and Non-Serious) Adverse Event measured to assess safety and tolerability [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. To determine and compare tumour-specific immunological activation in the peripheral blood in the experimental group and the control group. Number of patients in the respective arms with induction of Tumor specific CD8+ T Cells in PBMC [ Time Frame: 6 months ]
  2. To determine and compare immunological activation in tumour mass in the experimental group and the control Group. Number of patients in the respective arms with infiltration of CD8+ T Cells into tumours [ Time Frame: 6 months ]
  3. To determine and compare overall response rate in the experimental group and the control group by number of patients with PD, SD, PR and CR in the respective arms [ Time Frame: 6 months ]
  4. To determine and compare progression-free survival (PFS) in the experimental group and the control group by median time to progression in the respective arms [ Time Frame: 6 months ]
  5. To determine and compare overall survival (OS) in the experimental group and the control group [ Time Frame: Until death ]
  6. To analyse immunological activation by comparing patients with and without presence of tumour antigen recognizing CD8+ T cells [ Time Frame: 6 months ]
  7. To analyse clinical outcome by time to event endpoints (OS and PFS) [ Time Frame: 6 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent.
  • Male or female, ≥18 years of age.

  • Histologically confirmed unresectable (advanced) malignant pleural mesothelioma in patients who are not candidates for curative surgery and for whom therapy with pemetrexed in combination with cisplatin or carboplatin is considered appropriate. This include:

    • patients who are naïve to chemotherapy,
    • and those who have already received pemetrexed in combination with cisplatin or carboplatin to which their tumour initially responded, but they have relapsed after at least 6 months.

The patient may be evaluated by a multidisciplinary consultation (according to hospital procedure), however the final decision about the inclusion of a patient is made by the principal investigator.

  • Measurable disease according to Response Evaluation in Solid Tumour (RECIST 1.1).
  • Tumour must be accessible to intratumoural (i.t.) injections and to tumour core needle biopsy or thoracoscopy for tissue sampling and immunohistochemistry analysis.
  • The patients must be eligible to receive the study specific chemotherapies, including cyclophosphamide, according to the SPCs and local practice.
  • Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance score 0 to 1.
  • Acceptable liver, renal, and haematological functions.
  • All women of childbearing potential must have a negative urine or serum pregnancy test at screening and all patients must agree to use barrier contraception (i.e. condom) during study treatment and for 2 months after the last virus treatment, 6 months after the last dose of pemetrexed/cisplatin/carboplatin and 12 months after the dose of cyclophosphamide.

Exclusion Criteria:

  • Receipt of oncolytic virus treatment, or vaccination with a vaccine containing live virus within 4 weeks before Day 1.
  • Use of significant immunosuppressive medication, including high dose corticosteroid (defined as the equivalent of >10 mg/day prednisone) within 4 weeks before Day 1.
  • Patients who participated in a study with an investigational drug or device within 4 weeks prior to Day 1.
  • Active bacterial, viral, or fungal infections, requiring systemic therapy.
  • Severe arrhythmia, heart failure, previous cardiac infarction, or acute inflammatory heart disease.
  • Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient, if included in this study.
  • Known infection with HIV, hepatitis B, or hepatitis C.
  • Known brain metastases.
  • History of organ transplant.
  • Females who are pregnant or breast feeding.
  • Unwillingness or inability to comply with the study protocol for any reason.
  • Patients with pre-existing hearing loss or neuropathy that may worsen due to potential neurotoxicity from cisplatin.
  • Patients with a history of hypersensitivity to cisplatin or carboplatin or pemetrexed or cyclophosphamide (or any of its metabolites).
  • Patients who are taking phenytoin for prophylactic use.
  • History of malignant tumour, unless the patient has been without evidence of disease for at least 3 years, or the tumour was a non-melanoma skin tumour, cervical carcinoma in situ, or prostatic carcinoma in situ.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02879669


Locations
Layout table for location information
France
Centre Georges-François Leclerc
Dijon, France
CHU de Rennes - Pontchaillou
Rennes, France
Spain
Hospital Universitario Quirón
Barcelona, Spain
Vall d'Hebron Univerity Hospital
Barcelona, Spain
Hospital Universitari de Girona Doctor Josep Trueta - Institut Català d'Oncologia
Girona, Spain
Hospital 12 de octubre
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Sponsors and Collaborators
Targovax Oy
Theradex
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Targovax Oy
ClinicalTrials.gov Identifier: NCT02879669    
Other Study ID Numbers: ONCOS C719
2015-005143-13 ( EudraCT Number )
First Posted: August 26, 2016    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: October 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Mesothelioma
Mesothelioma, Malignant
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Pleural Neoplasms
Lung Diseases
Respiratory Tract Diseases
Cyclophosphamide
 Carboplatin
Pemetrexed
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Enzyme Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors